BDAZ - If, and that's a big if, the results come in close to what Nicholls et al (from slides presented at the Bio CEO Conference last month) reported at a 62% reduction in the group of patients that represent this trial profile then it would be closer to 12 and 4. Note that there was a very small number of patients in that profile in the previous trial. It would be a stretch to mirror those results but why not dream a little.

dyodd

tada